Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 507 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: EBRT Clear all
Completed Early Phase 1 Interventional Results available

Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

NCT00140556
View directory record Official record
Conditions
Head and Neck Cancer, Pharynx Cancer
Interventions
Chemoradiotherapy, Cisplatin, Bevacizumab, Erlotinib
Radiation · Drug
Lead sponsor
David M. Brizel, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 11, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Study of Stereotactic Body Radiotherapy vs. Conventional Radiation for Spine Metastasis

NCT01525745
View directory record Official record
Conditions
Primary Tumor, Metastatic Cancer
Interventions
Radiosurgery/SBRT, External Beam Radiation Therapy
Radiation
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer

NCT00006469
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Results available

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

NCT03253744
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasm
Interventions
18F-DCFPyL, Tumor Irradiation, Prostate + tumor irradiation
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer

NCT00557492
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
Drug · Radiation
Lead sponsor
Amer Zureikat
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 11, 2026, 5:14 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

NCT01622868
View directory record Official record
Conditions
HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Other · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 210 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 11, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

Pembro With Radiation With or Without Olaparib

NCT05568550
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pembrolizumab, Olaparib, Androgen Deprivation Therapy, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
Zin W Myint
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Lexington, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional

SBRT Boost for Unfavorable Prostate Cancer'

NCT02016248
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic body radiotherapy (SBRT) Boost
Radiation
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
3
States / cities
Fountain Valley, California • Laguna Hills, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Not listed Phase 2 Interventional

Accelerated Partial Breast Radiotherapy With Either Mammosite or Intensity Modulated Radiotherapy

NCT01185145
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Brachytherapy with Mammosite RTS, Intensity Modulated Radiotherapy
Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
40 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
6
States / cities
Aurora, Colorado • Boulder, Colorado • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 11, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

NCT02494700
View directory record Official record
Conditions
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage I Mantle Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage II Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma, Ocular Adnexal Lymphoma, Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma, Orbit Lymphoma
Interventions
External Beam Radiation Therapy, Orbital Radiation
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

NCT00573131
View directory record Official record
Conditions
Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
Interventions
OncoGel (Paclitaxel gel), cisplatin, 5-FU, radiation therapy, esophageal resection
Drug · Radiation · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

NCT00437372
View directory record Official record
Conditions
Cancer, Head and Neck Cancer, Pelvic Cancer, Nervous System Neoplasms, Thoracic Neoplasms
Interventions
Sunitinib, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Active, not recruiting Phase 3 Interventional

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

NCT03801876
View directory record Official record
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Docetaxel, Esophagectomy, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2036
U.S. locations
96
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

NCT03601455
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
Interventions
Durvalumab, External Beam Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 11, 2026, 5:14 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial

NCT05331131
View directory record Official record
Conditions
Cancer of Head and Neck, Mucositis Oral, Pharyngeal Mucositis
Interventions
Ketamine Topical
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Radiotherapy of Motor Deficits From Metastatic Epidural Spinal Cord Compression

NCT02189473
View directory record Official record
Conditions
Metastatic Epidural Spinal Cord Compression
Interventions
radiotherapy
Radiation
Lead sponsor
Prof. Dirk Rades, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

NCT01485731
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
Drug · Radiation · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 11, 2026, 5:14 PM EDT
Withdrawn Phase 1 Interventional

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer

NCT00118300
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
Interventions
capecitabine, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Sep 11, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional

Modernizing Instructions to Improve Treatment Participation of Subjects During Their First Radiotherapy

NCT06246409
View directory record Official record
Conditions
Cancer
Interventions
Modernized patient instructions, Existing patient instructions
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Recruiting Phase 3 Interventional

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

NCT03180268
View directory record Official record
Conditions
Grade 2 Meningioma, Intracranial Meningioma
Interventions
Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Procedure · Other · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
198
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional

Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)

NCT00630890
View directory record Official record
Conditions
Cholangiocarcinoma, Klatskin Tumor, Biliary Tract Cancer
Interventions
External beam radiation and Cyberknife radiosurgery boost and capecitabine
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Sep 11, 2026, 5:14 PM EDT
Terminated No phase listed Observational

Urodynamic Evaluation in Post-radiation Salvage Prostatectomy Patients

NCT00901420
View directory record Official record
Conditions
Prostate Cancer
Interventions
Urodynamics Test, Questionnaire
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 11, 2026, 5:14 PM EDT